News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia Ossificans Progressiva Based on Recommendations from Data Monitoring Committee (DMC)
MONTREAL, CANADA, APRIL 2, 2015  –  Clementia Pharmaceuticals Inc.  announced today that the Data Monitoring Committee (DMC) for the company’s Phase 2 adaptive‐design, dose‐ranging study of palovarotene for fibrodysplasia ossificans progressiva (FOP) has completed a planned review of
View HTML
Toggle Summary Clementia Pharmaceuticals Highlights Role of Patient Community in the Fight Against Fibrodysplasia Ossificans Progressiva (FOP)
Company to Host Webcast to Pay Tribute to FOP Community and Recognize Rare Disease Day MONTREAL, CANADA, February 24, 2015  –  Clementia Pharmaceuticals Inc.  will observe Rare Disease Day 2015 by hosting a webcast to commend patients and caregivers for their role in advancing basic
View HTML
Toggle Summary Clementia Completes Enrollment Of First Cohort In Phase 2 Clinical Trial!
Clementia is pleased to announce the enrollment of the 8th patient in Cohort 1 of its Phase 2 clinical trial of palovarotene for the treatment of FOP! This important milestone triggers the Data Monitoring Committee (DMC) review after this 8th patient completes the 42-day treatment period.
View HTML
Toggle Summary Clementia Pharmaceuticals Opens Clinical Trial Site in Europe for Phase 2 Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva (FOP)
MONTREAL, CANADA, January 12, 2015  –  Clementia Pharmaceuticals Inc.  today announced the opening of a new site in Paris, France for the Phase 2 clinical trial of palovarotene, the company’s lead product candidate for the treatment of fibrodysplasia ossificans progressiva (FOP).
View HTML
Toggle Summary Clementia Pharmaceuticals Raises $10 Million in Extension of Series A Financing to Support Development of Palovarotene for FOP
Company Opens New Subsidiary to Serve U.S. Market MONTREAL, CANADA, January 5, 2015  –  Clementia Pharmaceuticals Inc.  today announced that it has secured an additional $10 million from current investors to support development of the company’s lead compound palovarotene for the
View HTML
Toggle Summary Clementia Pharmaceuticals Initiates First Prospective Natural History Study in Patients with Fibrodysplasia Ossificans Progressiva (FOP)
MONTREAL, CANADA, DECEMBER 17, 2014  –  Clementia Pharmaceuticals Inc.  announced today the initiation of a natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of
View HTML
Toggle Summary Clementia Pharmaceuticals Receives Fast Track Designation for Palovarotene for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
MONTREAL, CANADA, December 1, 2014  –  Clementia Pharmaceuticals Inc.  announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
View HTML
Toggle Summary Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA, NOVEMBER 21, 2014  –  Clementia Pharmaceuticals Inc.  announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company’s lead product candidate, for the treatment of fibrodysplasia ossificans
View HTML
Toggle Summary Phase 2 Clinical Trial Milestone
Clementia Completes Enrollment Of First Cohort In Phase 2 Clinical Trial! February 5, 2015: Clementia is pleased to announce the enrollment of the 8th patient in Cohort 1 of its Phase 2 clinical trial of palovarotene for the treatment of FOP! This important milestone triggers the Data Monitoring
View HTML
Toggle Summary Clementia Pharmaceuticals Announces Open-Label Phase 2 Extension Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA, OCTOBER 27, 2014  –  Clementia Pharmaceuticals Inc.  announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful,
View HTML